Preclinical, Publications Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
Preclinical, Publications Discovery of novel HDV entry inhibitors with selectivity over bile acid inhibition
Preclinical, Publications Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer
Preclinical, Publications ALG-098340, an Investigational, Potent, Pan-Coronavirus 3CLPRO Inhibitor for Pandemic Preparedness
Preclinical, Publications Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-1/PD-L1 Inhibitor Targeting PD-L1 Dimerization, Internalization and Degradation
Preclinical, Publications Preclinical Characterization of ALG-094295, a Highly Potent and Orally Bioavailable Small Molecule PD-1/PD-L1 Inhibitor Targeting Dimerization, Internalization and Degradation of PD-L1
Preclinical, Publications Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis